Clinically proven to work
About 900,000 women are diagnosed with breast cancer yearly, according to the World Health Organization, (WHO). Erythema occurs in 80-90 percent of women treated for breast cancer with radiation therapy. Currently, there is no standard treatment for radiation-induced skin reactions. This study is the first to prove a clinically effective treatment that would make life a lot easier for women with breast cancer undergoing radiation therapy.
Twenty-four patients were presented with 34 erythematous areas of skin. Areas of skin from the same woman were in different areas of the breast, each receiving a different radiation dose. Each affected area was divided into two halves, one treated with Mepilex Lite dressings and the other with the standard aqueous cream. The results showed a significant reduction of the radiation-induced erythema compared to the aqueous cream. Mepilex showed an average increase in RISRASi score to 1.7 when the aqueous cream saw an increase of 2.4.
The investigator stated that not only did Mepilex Lite show a clear reduction of radiation-induced erythema, but that the majority of the women also preferred the dressings over the cream and thought they increased the comfort levels. It was also reported that the amount of pain experienced decreased and the treatment allowed the women to wear normal clothing.
For more information: www.bjr.birjournals.org